复方黄柏液、牛黄痔清栓联合常规疗法治疗肛隐窝炎临床研究  

Clinical Study on Compound Huangbai Liquid and Niuhuang Zhiqing Suppository Combined with Conventional Therapy for Anal Cryptitis

作　　者：闵连永 徐芳 商湘 MIN Lianyong;XU Fang;SHANG Xiang(Xinyang Central Hospital,Xinyang Henan 464000,China)

机构地区：[1]信阳市中心医院,河南信阳464000

出　　处：《新中医》2024年第17期63-68,共6页New Chinese Medicine

摘　　要：目的:观察复方黄柏液联合牛黄痔清栓治疗湿热下注型肛隐窝炎的临床疗效。方法:选取120例湿热下注型肛隐窝炎患者,按随机数字表法分为A组、B组、C组、D组各30例。A组给予常规治疗,B组给予常规治疗联合复方黄柏液治疗,C组给予常规治疗联合牛黄痔清栓治疗,D组给予常规治疗联合复方黄柏液、牛黄痔清栓治疗。4组均治疗30 d。比较4组临床疗效及症状消退时间,比较4组治疗前后中医证候积分、血清指标值[单核细胞趋化蛋白-1(MCP-1)、P物质(SP)、5-羟色胺(5-HT)]、免疫指标值[T淋巴细胞亚群CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)]的变化。结果:A组临床疗效总有效率为70.00%、B组为86.67%、C组为83.33%、D组为100%,D组临床疗效高于其他3组,差异有统计学意义(P<0.05)。治疗后,4组中医证候主症、次症总积分均较治疗前下降(P<0.05);D组中医证候主症、次症总积分均低于A组、B组、C组(P<0.05)。治疗后,4组MCP-1、SP、5-HT指标值均较治疗前下降(P<0.05);D组MCP-1、SP、5-HT指标值均低于A组、B组、C组(P<0.05)。治疗后,4组CD4^(+)、CD4^(+)/CD8^(+)指标值均较治疗前升高(P<0.05),CD8^(+)指标值较治疗前下降(P<0.05);D组CD4^(+)、CD4^(+)/CD8^(+)指标值高于A组、B组、C组(P<0.05),CD8^(+)指标值低于A组、B组、C组(P<0.05)。D组肛门坠胀、肛门疼痛、肛门潮湿、肛门水肿消退时间均短于A组、B组、C组,B组、C组症状消退时间均短于A组,差异均有统计学意义(P<0.05)。结论:复方黄柏液、牛黄痔清栓联合常规疗法治疗湿热下注型肛隐窝炎能缓解症状,提高机体免疫功能,缩短症状恢复时间,疗效较好。Objective:To observe the clinical effect of Compound Huangbai Liquid and Niuhuang Zhiqing Suppository combined with conventional therapy on anal cryptitis of damp-heat pouring downward type.Methods:A total of 120 patients with anal cryptitis of damp-heat pouring downward type were selected and divided into Groups A,B,C and D according to random number table method,with 30 cases in each group.Group A was given conventional treatment;Group B was given conventional treatment combined with Compound Huangbai Liquid;Group C was given conventional treatment combined with Niuhuang Zhiqing Suppository,and Group D was given conventional treatment combined with Compound Huangbai Liquid and Niuhuang Zhiqing Suppository.Four groups were treated for 30 days.The clinical effects and symptom remission time in the four groups were compared,and the changes of traditional Chinese medicine syndrome scores,serum indexes[monocyte chemotactic protein-1(MCP-1),substance P(SP),5-hydroxytryptamine(5-HT)]and immune indexes[T lymphocyte subsets CD4^(+),CD8^(+),CD4^(+)/CD8^(+)]before and after treatment were compared between the four groups.Results:The total effective rate was 70.00%in Group A,86.67%in Group B,83.33%in Group C and 100%in Group D.The clinical effect in Group D was better than those in the other three groups,the difference being significant(P<0.05).After treatment,the total scores of main symptoms and secondary symptoms in the four groups were decreased when compared with those before treatment(P<0.05);the total scores of main symptoms and secondary symptoms in Group D were lower than those in Groups A,B and C(P<0.05).After treatment,the levels of MCP-1,SP and 5-HT in Group D were lower than those in Groups A,B and C(P<0.05);the levels of MCP-1,SP and 5-HT in Groups B and C were lower than those in Group A(P<0.05).After treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)were enhanced when compared with those before treatment(P<0.05),and the levels of CD8^(+)were reduced when compared with those before treatment(P<0.05);the leve

关 键 词：肛隐窝炎 湿热下注型 复方黄柏液 牛黄痔清栓 中医证候积分 症状消退时间 

分 类 号：R266[医药卫生—中医外科学]